Increased Doses of Adalimumab are Associated With Clinical Improvement of Hidradenitis Suppurativa
Journal of Drugs in Dermatology · 01.06.2023 · 22 (6) · 615-618
DOI: 10.36849/jdd.6868 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Drugs in Dermatology, online erschienen am 01.05.2023. Verfasst von Jazzmin Williams und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa. Die Arbeit wurde bisher 14-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Williams, J., Guzik, C., Wadhera, A., & Naik, H. (2023). Increased Doses of Adalimumab are Associated With Clinical Improvement of Hidradenitis Suppurativa. Journal of Drugs in Dermatology, 22(6), 615-618. https://doi.org/10.36849/jdd.6868
Vancouver
Williams J, Guzik C, Wadhera A, Naik H. Increased Doses of Adalimumab are Associated With Clinical Improvement of Hidradenitis Suppurativa. Journal of Drugs in Dermatology. 2023;22(6):615-618. doi:10.36849/jdd.6868
BibTeX
@article{Williams2023,
author = {Williams, Jazzmin and Guzik, Claudia and Wadhera, Akhil and Naik, Haley},
title = {Increased Doses of Adalimumab are Associated With Clinical Improvement of Hidradenitis Suppurativa},
journal = {Journal of Drugs in Dermatology},
year = {2023},
volume = {22},
number = {6},
pages = {615--618},
doi = {10.36849/jdd.6868}
}
EUVIMED